quetiapine-fumarate has been researched along with Leukopenia* in 13 studies
13 other study(ies) available for quetiapine-fumarate and Leukopenia
Article | Year |
---|---|
Increased infection rates associated with second-generation antipsychotics.
Topics: Antipsychotic Agents; Drug Labeling; Humans; Leukopenia; Olanzapine; Quetiapine Fumarate; Respiratory Tract Infections; Risk Factors | 2021 |
Safety of a Clozapine Trial Following Quetiapine-Induced Leukopenia: A Case Report.
The clozapine-derivative quetiapine has been shown in some cases to cause leukopenia and neutropenia.. We reported on a case of a young female diagnosed with treatment-resistant schizophrenia. After failed trials of three antipsychotic medications and despite a history of quetiapineinduced leukopenia, clozapine treatment was introduced due to the severity of the patient's symptoms, the limited effective treatment options, and a lack of guidelines on this issue.. Over a ten-week period of clozapine treatment at 700 mg per day, the patient developed agranulocytosis. Her white blood cell count sharply dropped to 1.6 × 10. The safety of clozapine in a patient who has previously experienced leukopenia and neutropenia with quetiapine requires further investigation. Increased attention should be paid to such cases. Careful monitoring and slow titration are advisable. Topics: Adult; Antipsychotic Agents; Clozapine; Female; Humans; Leukopenia; Quetiapine Fumarate; Schizophrenia; Treatment Outcome | 2019 |
Leukocytopenia in patients treated with multiple antipsychotics, including aripiprazole and quetiapine.
Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Humans; Leukopenia; Quetiapine Fumarate | 2017 |
Quetiapine-associated leucopenia and thrombocytopenia: a case report.
There have been few reports regarding quetiapine-associated hematological effects other than white-blood-cell alteration. We present the first reported Han-Chinese case that developed leucopenia and thrombocytopenia after taking quetiapine.. We present a case of a person with a bipolar I disorder who experienced leucopenia and thrombocytopenia after taking 400 mg/day of quetiapine and 1000 mg/day of valproic acid for three and one-half months. The hematological toxicity abated upon the discontinuation of both drugs. However, due to the intolerable side effects of the replaced antipsychotic (haloperidol), and according to the patient's preference, we prescribed quetiapine and valproic acid again. There was a recurrence of leucopenia and a decreased platelet count by the sixth day. The adverse effects disappeared soon after we discontinued quetiapine, while keeping valproic acid treatment.. Quetiapine-associated leucopenia and thrombocytopenia seems reversible but possibly fatal. Therefore, clinical practitioners should be aware of this adverse reaction. Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Leukopenia; Male; Quetiapine Fumarate; Thrombocytopenia; Young Adult | 2015 |
Quetiapine-induced leucopenia.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Humans; Leukopenia; Male; Quetiapine Fumarate; Schizophrenia | 2010 |
Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents.
At the Austin State Hospital, Austin, TX, a number of cases of neutropenia and leukopenia have been observed in children and adolescents who were treated with the combination of valproate and quetiapine. Use of this combination has raised concerns regarding an increased risk of hematologic toxicity.. To evaluate the incidence of leukopenia and neutropenia associated with the use of valproate, quetiapine, or the combination in the child and adolescent population.. This study was a retrospective evaluation of patients from the child and adolescent psychiatric service of the Austin State Hospital who were treated with valproate, quetiapine, or the combination. Subjects were selected from patients discharged between August 1, 2004, and August 31, 2007. Laboratory data were evaluated to determine the incidence and severity of leukopenia and neutropenia associated with valproate, quetiapine, and a combination of the 2.. A total of 131 patients were included in the study. Analysis of the laboratory data revealed a combined incidence of neutropenia and/or leukopenia of 44%, 26%, and 6% in the combination group, valproate monotherapy group, and quetiapine monotherapy group, respectively. Differences in the incidence of neutropenia and/or leukopenia between the quetiapine monotherapy group and valproate monotherapy group, as well as the quetiapine monotherapy group and the combination group reached statistical significance. A significant difference was found among groups based on absolute neutrophil count Common Toxicity Criteria severity (p < 0.001). The combination group differed significantly in incidence of moderate-to-severe neutropenia (14 cases) from both the valproate (5 cases) and quetiapine (0 cases) monotherapy groups. A significantly greater number (44%) of African American patients experienced neutropenia and/or leukopenia than white (not Hispanic or Latino; 29%) or Hispanic or Latino (11%) patients.. Patients treated with valproate or the combination of valproate and quetiapine should be monitored for the occurrence of leukopenia and neutropenia. Controlled studies are warranted to examine possible pharmacokinetic and pharmacodynamic interactions with the combination of valproate and quetiapine to further evaluate the hematologic findings of this study. Topics: Adolescent; Anticonvulsants; Child; Dibenzothiazepines; Drug Therapy, Combination; Female; Hospitalization; Humans; Incidence; Leukopenia; Male; Neutropenia; Quetiapine Fumarate; Retrospective Studies; Severity of Illness Index; Valproic Acid | 2009 |
[Quetiapine-induced leucopenia].
We describe the case of a 20-year-old man with schizophrenia who was treated with the dibenzothiazepine antipsychotic drug quetiapine in oral doses of 900 mg daily. At admission the patient had a normal blood count. 15 weeks after initiation of treatment asymptomatic cytopenia was discovered with leucocytes of 2.2 billion/l and thrombocytes of 114 billion/l. Two weeks after discontinuation of quetiapine the leucopenia subsided. Physicians should be aware of leucopenia as a potential adverse effect to quetiapine, especially in patients with symptoms of infections or cytopenia. Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Humans; Leukopenia; Male; Quetiapine Fumarate; Schizophrenia | 2008 |
Non-life-threatening leukopenia in a renal transplant recipient with acute overdose of mycophenolate mofetil.
Mycophenolate mofetil (MMF) is increasingly used as an immunosuppressant for organ transplantation and for treatment of autoimmune diseases. As yet, the experience with acute overdose of MMF in humans is limited. Herein we have reported a 40-year-old female kidney recipient with moderate leukopenia and lack of gastrointestinal toxicity following ingestion of 25 g MMF, which was confirmed by serum drug levels. We treated the patient with charcoal decontamination and oral cholestyramine. She recovered completely without sequelae. Topics: Adult; Antidepressive Agents; Benzodiazepines; Charcoal; Cholestyramine Resin; Depressive Disorder; Diazepam; Dibenzothiazepines; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Leukopenia; Mycophenolic Acid; Quetiapine Fumarate; Renal Dialysis; Valproic Acid | 2008 |
Is aripiprazole the only choice of treatment of the patients who developed anti-psychotic agents-induced leucopenia and neutropenia? A case report.
Leucopenia and neutropenia could be side effects of anti-psychotic drugs, especially clozapine. However, there is evidence that other anti-psychotics can cause leucopenia and neutropenia. We present the clinical follow-up and treatment process of a patient, who had initially developed quetiapine and amisulpride related neutropenia, but not with aripiprazole. Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Blood Cell Count; Dibenzothiazepines; Female; Humans; Leukopenia; Neutropenia; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sulpiride | 2008 |
Leukopenia and neutropenia induced by quetiapine.
Leukopenia and neutropenia are recognised as side effects of antipsychotic medication, notably clozapine. A case is presented in which a female Caucasian patient who had previously developed these side effects with clozapine also developed them with quetiapine in conjunction with semisodium valproate. There was no such reaction to zuclopenthixol, sulpiride, olanzapine and aripiprazole. It is concluded that caution should be exercised when treating with quetiapine especially where there has been neutropenia with a previous antipsychotic agent. Topics: Adult; Antimanic Agents; Antipsychotic Agents; Dibenzothiazepines; Drug Resistance; Female; Humans; Leukopenia; Neutropenia; Quetiapine Fumarate; Recurrence; Schizophrenia; Valproic Acid | 2007 |
[Sustained leukopenia probably related to quetiapine].
Topics: Agranulocytosis; Antipsychotic Agents; Bipolar Disorder; Clozapine; Dibenzothiazepines; Female; Humans; Leukopenia; Middle Aged; Quetiapine Fumarate | 2005 |
Quetiapine-induced leucopenia: possible dosage-related phenomenon.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Leukopenia; Quetiapine Fumarate; Schizophrenia | 2003 |
Quetiapine and leukopenia.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Female; Humans; Leukocyte Count; Leukopenia; Psychotic Disorders; Quetiapine Fumarate | 2001 |